








Supplementary Figure 1: A) Representative images showing IFN γ spots against the most immunogenic peptide pools derived from the TCR α chain. B) Representative images showing IFN γ spots against the most immunogenic peptide pools derived from the TCR β chain. C) Representative images showing IFN γ spots against the most immunogenic peptide pools derived from the TCR γ chain.




Supplementary Figure 2: Safety of targeting TCR using the TCRfullvax. A) Mean number of splenocytes in naïve mice vs mice vaccinated with TCRfullvax. B) Percentage of Live CD3+ T cells amongst splenocytes in naïve mice vs mice immunized with TCRfullvax (n=5 mice/group).



Supplementary Figure 3: Flow cytometry analysis demonstrating CD4+ and CD8+ T cell responses elicited by TCRfullvax




Supplementary Figure 4: A) EL4 tumor size of each mouse treated with either pvax or TCRfullvax. B) Proportion of intra-tumoral CD8+ T cells that are KLRG1-PD1+, KLRG1-PD1-, KLRG1+ PD1+ or KLRG1+ PD1- in pvax vs TCRfullvax treated mice. C) Comparison of KLRG1+ PD1+, KLRG1-PD1+, KLRG1-PD1- and KLRG1+ PD1- intratumoral CD8+ T cells in pvax vs TCRfullvax treated mice. D) Ratio KLRG1+ PD1+, KLRG1-PD1+, KLRG1-PD1- and KLRG1+ PD1- intratumoral CD8+ T cells in pvax vs TCRfullvax treated mice of E)PD1 MFI on intra-tumoral CD8+ Tcm cells. F) PD1 MFI on intra-tumoral CD8+ Teff cells. G) KLRG1 MFI on intra-tumoral CD8+ Tcm cells. H) KLRG1 MFI on intra-tumoral CD8+ Teff cells




Supplementary Figure 5: Gating strategy for TCR Vβ12 expression in EL4 tumors

Gated on TCRβ+ Cells



Supplementary Figure 6: Decreased expression of TCRVβ12 in response to TCRfullvax



Supplementary Figure 7: Expression of A) IFN γ , B) TNF α and C) IL2 from CD8+ and CD4+ T cells generated by EL4neovax